

IN THE DRAWINGS:

Please substitute Figure 1 with the attached replacement drawing sheet. The attached replacement drawing sheet includes the symbol for the Eclipse, High Flow data points in the Key and more legibly shows the Eclipse, High Flow data line and data points. In addition, the title of the graph has been removed.

REMARKS

Claims 1, 3-5, and 11-15, and 21-34 have been allowed.

The Examiner requested clarification of the Specification as below.

1. With respect to Figure 1, the Examiner states that the “key appears to be missing the symbol from for “Eclipse, High flow”. The Examiner also states that the graph only shows two lines rather than three, and also asks if the data for the high and low flow settings for the Eclipse device are essentially identical.

Figure 1 is being substituted with a replacement sheet which more clearly shows the key and lines. Note that the data lines for the high and low flow settings of the Eclipse device from about 0.3 hours post dose and onwards are located close to each other; and further that the first data point of the Eclipse High Flow data is shown as black mark overlapping the error bar of the first point of the Eclipse Low Flow data, in the originally filed Figure 1. The Drawings description and the text of the Specification also discusses the Eclipse, Low Flow and High flow data points and lines. Thus no new matter is being added, and entry of Figure 1 is respectfully requested.

2. The Examiner further requests the meaning of the acronyms MDI, DPI, DSPC, FPD, and SWFI at certain locations in the application. Applicant respectfully submits that these terms are well known in the art and have been defined in the Specification, nevertheless, Applicant is providing substitute amendment paragraphs for the Specification which state the meaning of the acronyms.

3. On page 21, line 6, the acronym PS_{bud} means a Pulmosphere® particle made with budesonide, as recited in the amended paragraph.


4. Applicant confirms that PulmoSphere® is a registered trademark of the assignee of the present application, Nektar Therapeutics, and that an exemplary embodiment of such particles is described in Example 1 on page 19.
5. On page 21, line 12, flow should begin with a capital letter as in line 15, and this is being corrected.
6. On page 21, line 25, a space has been inserted after "from".
7. The On page 23 in the heading for Table 4B, the "s" in Pulmosphere should be capitalized as in lines 21 and 24.
8. On page 10, lines 15 and 16; page 11, lines 7 and 8; and page 15, line 9, "etc." has been substituted with "and the like" as requested by the Examiner.
9. On page 17, a period "." has been placed on the last line.

The above-discussed amendments are believed to place the present application in condition for allowance. Should the Examiner have any questions regarding the above remarks, the Office Action is requested to telephone Applicant's representative at the number listed below.

Respectfully submitted,
JANAH & ASSOCIATES, P.C.

Date: November 28th, 2007

By:


Ashok Janah
Reg. No. 37,487

Please direct telephone calls to: Ashok K. Janah at (415) 538-1555.